Association of polypharmacy and potential drug‐drug interactions with adverse treatment outcomes in older adults with advanced cancer

Abstract

In a cohort of older adults with advanced cancer, polypharmacy and PDIs were associated with an increased risk of adverse treatment outcomes. Providing meaningful screening and interventional tools to optimize medication use may improve treatment-related outcomes in these patients.